NoCopi Technologies GAAP EPS of $0.12, revenue of $3.33M

NoCopi Technologies reported Q3 GAAP EPS of $0.12 and revenue of $3.33M, up 753.8% year-over-year. The company also reported net cash used in operating activities of $(0.366) million for the nine months ended September 30, 2026, compared to net cash provided of $0.658 million in the prior period, according to the company.

Original reporting
Published Nov 13, 2026, 6:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NNUP
Bullish
medium confidence
Mentioned
$NNUP
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$NNUPBullishMed
01

Why it matters

The earnings release provides the first public data for the quarter, offering a fresh trading signal for the micro‑cap.

02

Market read

New earnings data for a low‑cap stock may trigger short‑term price movement.

03

What to watch

Potential cash burn and lack of operating cash flow could temper enthusiasm.

Relevance 6/10Novelty 8/10Timing: today

Background

NoCopi Technologies issued a press release announcing its Q3 results.

Company-level read

Ticker impact

$NNUPBullishMedium confidence
Context

Q3 GAAP EPS of $0.12 and revenue of $3.33M reported for NoCopi Technologies.

Expected impact

potential modest upside as earnings exceed expectations for a micro‑cap.

Evidence & confidence

New earnings numbers provide fresh data; investors may bid the stock higher on the surprise revenue jump.

Market effects

Limited to niche tech/AI micro‑cap space; no broader sector impact.

U.S. OTC market only.

Low

Counterpoint

Given the tiny scale, the earnings beat may be priced in quickly, limiting upside.

Key entities

  • NoCopi Technologies

    Micro‑cap technology firm reporting Q3 earnings.

Related articles

$NNUPMed

Nocopi Technologies Reports Third Quarter Results

NOCOPI TECHNOLOGIES INC/MD/ (NNUP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nocopi Technologies Reports Third Quarter Results KING OF PRUSSIA, PA – November 12, 2026 – Nocopi Technologies, Inc. (“Nocopi Technologies” or the “Company”; OTCQB: NNUP) today reported financial results for the quarter ended September 30, 2026. 2026 Third Quarter H

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).